X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GAD-alum,Vitamin D2
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The results support a precision medicine approach with Diamyd® where significant effect on the preservation of endogenous insulin producing capacity and improved blood glucose control was seen in individuals that carry a specific genotyp, HLA DR3-DQ2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GAD65-alum,Vitamin D2
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
The patients, diagnosed with type 1 diabetes, have been given the diabetes vaccine Diamyd® directly into the lymph node on three occasions, one month apart, in combination with oral vitamin D (or its placebo) during four months, starting 30 days prior to the first injection.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
